Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

suredubb May. 13 at 7:43 AM

$TCRX New therapies working great they save lives and are an important treatment huge multi billion market for lead drug and new treatments going clinical

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX added more at 1.12 ... bought 3x this month.

0 · Reply

JSP_Dilution_Player May. 12 at 3:11 PM

$TCRX presentation after hours today and more catalysts this QTR. Trading under cash. Well known TUTES as well

0 · Reply

xpro123 May. 12 at 1:49 PM

$TCRX adding more. Feels like a great chance for a home run

0 · Reply

suredubb May. 11 at 9:59 PM

$TCRX ASGCT is a big deal

0 · Reply

suredubb May. 11 at 9:56 PM

$TCRX hopefully updated info tomorrow.. things are good so far

0 · Reply

JSP_Dilution_Player May. 11 at 8:32 PM

$TCRX presentation is tomorrow from 5 PM EST to 6:30 PM EST. Management needs to drop good PR :)

0 · Reply

kubota2323 May. 10 at 7:57 PM

$TCRX up to 20000 bags now.

0 · Reply

suredubb May. 9 at 6:03 AM

$TCRX short interest low and decreasing… that means there isn’t money to be made on downside… another massive bullish indicator great time to get in and grab your nuts

0 · Reply

TScan Therapeutics reports Q1 EPS (22c), consensus (17c)

May 6, 2026, 7:00 AM EDT - 7 days ago

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 27, 2026, 4:30 PM EDT - 15 days ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

Apr 15, 2026, 3:00 PM EDT - 27 days ago

TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:00 AM EDT - 5 weeks ago

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

2026-03-05T14:05:02.000Z - 2 months ago

TScan Therapeutics price target raised to $5 from $4 at Wedbush

Mar 4, 2026, 11:50 AM EST - 2 months ago

TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T12:11:24.000Z - 2 months ago

TScan Therapeutics reports Q4 EPS (18c), consensus (28c)

2026-03-04T12:10:31.000Z - 2 months ago

TScan Therapeutics sees cash runway into 2H27

Mar 4, 2026, 7:00 AM EST - 2 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-26T12:36:57.000Z - 2 months ago

TScan Therapeutics completes enrollment into Cohort C of ALLOHA study

Feb 26, 2026, 7:00 AM EST - 2 months ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 2 months ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 8, 2025, 8:00 AM EST - 5 months ago

TScan Therapeutics Transcript: KOL Event

2025-12-07T18:30:11.000Z - 5 months ago

TScan Therapeutics announces updated data from ALLOHA Phase 1 trial

Dec 3, 2025, 4:05 PM EST - 5 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

2025-11-14T00:55:25.000Z - 6 months ago

TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Nov 12, 2025, 10:00 AM EST - 6 months ago

TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T12:10:19.000Z - 6 months ago

TScan Therapeutics reports Q3 EPS (28c), consensus (33c)

Nov 12, 2025, 7:00 AM EST - 6 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 6 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

2025-11-04T11:16:37.000Z - 6 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-04T11:10:09.000Z - 6 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-03T19:05:38.000Z - 6 months ago

TScan Therapeutics price target lowered to $6 from $9 at Needham

Nov 3, 2025, 8:00 AM EST - 6 months ago

TScan Therapeutics Transcript: FDA Announcement

2025-11-03T11:50:39.000Z - 6 months ago

TScan Therapeutics to reduce workforce by 30%

Nov 3, 2025, 6:30 AM EST - 6 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 10, 2025, 9:00 AM EDT - 8 months ago

TScan Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 5:35 PM EDT - 8 months ago

TScan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

2025-08-12T11:05:34.000Z - 9 months ago

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-08-12T11:05:19.000Z - 9 months ago

TScan Therapeutics expects cash to fund operations into Q1 of 2027

Aug 12, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 4, 2025, 4:55 PM EDT - 1 year ago

TScan Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 13, 2025, 6:40 PM EDT - 1 year ago

TScan Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

2025-05-12T19:00:24.000Z - 1 year ago

TScan Therapeutics management to meet virtually with BTIG

2025-05-07T10:16:13.000Z - 1 year ago

TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright

2025-05-06T11:06:17.000Z - 1 year ago

TScan Therapeutics reports Q1 EPS (26c), consensus (28c)

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Apr 7, 2025, 9:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

2025-03-27T11:25:33.000Z - 1 year ago

TScan Therapeutics appoints Camiolo as SVP, Market Access

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

2025-03-14T12:07:12.000Z - 1 year ago

TScan Therapeutics assumed with an Overweight at Morgan Stanley

Mar 5, 2025, 1:10 PM EST - 1 year ago

TScan Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:00 AM EST - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Transcript: Status Update

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Sep 10, 2024, 9:00 AM EDT - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

suredubb May. 13 at 7:43 AM

$TCRX New therapies working great they save lives and are an important treatment huge multi billion market for lead drug and new treatments going clinical

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX $GERN $PMVP 3 biggies bet and still holding

0 · Reply

GangsterX May. 12 at 6:12 PM

$TCRX added more at 1.12 ... bought 3x this month.

0 · Reply

JSP_Dilution_Player May. 12 at 3:11 PM

$TCRX presentation after hours today and more catalysts this QTR. Trading under cash. Well known TUTES as well

0 · Reply

xpro123 May. 12 at 1:49 PM

$TCRX adding more. Feels like a great chance for a home run

0 · Reply

suredubb May. 11 at 9:59 PM

$TCRX ASGCT is a big deal

0 · Reply

suredubb May. 11 at 9:56 PM

$TCRX hopefully updated info tomorrow.. things are good so far

0 · Reply

JSP_Dilution_Player May. 11 at 8:32 PM

$TCRX presentation is tomorrow from 5 PM EST to 6:30 PM EST. Management needs to drop good PR :)

0 · Reply

kubota2323 May. 10 at 7:57 PM

$TCRX up to 20000 bags now.

0 · Reply

suredubb May. 9 at 6:03 AM

$TCRX short interest low and decreasing… that means there isn’t money to be made on downside… another massive bullish indicator great time to get in and grab your nuts

0 · Reply

kubota2323 May. 9 at 12:21 AM

$TCRX Cash Position: Cash and cash equivalents as of March 31, 2026, were $128.1 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to fund its current operating plan into the second half of 2027.

0 · Reply

signaljumper May. 8 at 4:56 PM

$TCRX a Close above 1.30 and WE will See the Gap Close in the coming 2 weeks

0 · Reply

signaljumper May. 8 at 1:43 PM

$TCRX adding at this Level Gap Close will come

0 · Reply

kubota2323 May. 8 at 1:43 PM

$TCRX welp

0 · Reply

kubota2323 May. 8 at 1:42 PM

$TCRX welp

0 · Reply

suredubb May. 8 at 6:36 AM

$TCRX major institutional investors involved…

0 · Reply

suredubb May. 8 at 6:35 AM

$TCRX nice PT if all goes well…

0 · Reply

Tonyboner May. 7 at 3:07 PM

$TCRX Long at $1.175

0 · Reply

suredubb May. 7 at 6:31 AM

$TCRX Lynx Capital… $16 million investment in TCRX

0 · Reply

suredubb May. 7 at 6:29 AM

$TCRX Lynx Capital dropped $16 million a few months back on TCRX Company is acting excited to share data.. hopefully it’s amazing good time to get a position.. volatile and always risk involved.. know your limits

0 · Reply

PenkeInvesting May. 7 at 5:13 AM

Fundamental analysis of $TCRX (TScan Therapeutics, Inc.) based on financial data and reported results. #TCRX #TScan

0 · Reply

JSP_Dilution_Player May. 6 at 10:03 PM

$TCRX who is hitting this after hrs

0 · Reply

Market Cap	67.14M
Revenue (ttm)	10.33M
Net Income (ttm)	-129.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.24%
Debt to Equity Ratio	0.34

Volume	894,200
Avg Vol	959,222
Day's Range	N/A - N/A
Shares Out	56.90M
Stochastic %K	24%
Beta	1.06
Analysts	Strong Sell
Price Target	$6.80